Sample result

GLP-1, a diabetes hormone

A saved result, shown read-only. Sign in to run your own searches. A new account gets a free 30-day trial.

The search

Query: GLP-1 · 31 lettersHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
From: UniProt P01275, residues 98 to 128
Search: Protein → Patent proteins · Automatic (Smith-Waterman)
Set: Public patent sequences: Patent proteins, snapshot 2026-11-05-c456f6bdba29
Ran: 2026-11-12
Found: 5,000 sequences, 3,061 publications, 1,851 families

Smith-Waterman compares each query with every stored sequence. Each query returns up to 5,000 sequences, with the best alignment of each. FASTA36 fits its E-values to a random sample of scores, so a sequence near the cutoff can come and go between runs. These results do not establish patentability.

Patents

3,061 publications in 1,851 families match these filters.

JP 2020521765-A2020-07-27

Therapeutic Uses of Dulaglutide

Eli Lilly and Company

Query Match 88.2%Identity 90.3%Family of 8
Best alignment and family
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
Family of 8
Grouped by the same title and applicant. No priority claim is on record.
- JP 2020521765-A2020-07-27
- KR 1020210134713-A2021-11-10
- KR 1020220132606-A2022-09-30
- JP 2023513054-A2023-03-30
- KR 1020230132627-A2023-09-15
- US 11890325-B22024-02-06
- JP 2025000602-A2025-01-07
- KR 1020250005518-A2025-01-09
WO 2020190591-A12020-09-24

PRESERVED FORMULATIONS

LILLY CO ELI

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
WO 2020204998-A12020-10-08

THERAPEUTIC USES OF DULAGLUTIDE

LILLY CO ELI

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
KR 1020210062053-A2021-05-28

GLP1-FC FUSION PROTEIN AND CONJUGATE THEREOF

JIANGSU GENSCIENCES INC

Query Match 88.2%Identity 90.3%Family of 3
Best alignment and family
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
Family of 3
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020210062053-A2021-05-28
- EP 3858866-A12021-08-04
- JP 2022501405-A2022-01-06
EP 3848388-A12021-07-14

FUSION POLYPEPTIDE COMPRISING POLYPEPTIDE REGION THAT CAN BE O-GLYCOSYLATED

LG CHEMICAL LTD

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
JP 2021535746-A2021-12-23

FUSION POLYPEPTIDE COMPRISING POLYPEPTIDE REGION THAT CAN BE O-GLYCOSYLATED

LG CHEM LTD

Query Match 88.2%Identity 90.3%Family of 2
Best alignment and family
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
Family of 2
Grouped by a shared priority claim, KR 10-2018-0105741.
- JP 2021535746-A2021-12-23
- JP 2023086836-A2023-06-22
JP 2022518850-A2022-03-16

FIBROBLAST GROWTH FACTOR 21 VARIANT, AND FUSION PROTEIN AND USE THEREOF

BEIJING SHUANGYIN BIOTECHNOLOGY CO LTD,Haifeng DUAN

Query Match 88.2%Identity 93.1%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
JP 2022525883-A2022-05-20

Preserved Formulations

Eli Lilly and Company

Query Match 88.2%Identity 90.3%Family of 2
Best alignment and family
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- JP 2022525883-A2022-05-20
- JP 2023123742-A2023-09-05
KR 1020220069610-A2022-05-27

Novel fusion protein comprising FGF19 variant, and use thereof

Alteogen, Inc

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
KR 1020220079415-A2022-06-13

Fusion protein comprising glucagon like peptide-1 receptor agonist and anti-OSCAR antibody and uses thereof

ImmunoForge Co.,Ltd

Query Match 88.2%Identity 90.3%Family of 2
Best alignment and family
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020220079415-A2022-06-13
- JP 2023551970-A2023-12-13
JP 2022551511-A2022-12-09

Materials and Methods for Mass Spectrometric Protein Analysis

JANSSEN BIOTECH INC,Harsha Gunawardena,Hirsh Nanda

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
JP 2023002547-A2023-01-10

Dulaglutide for the treatment of chronic kidney disease

Eli Lilly and Company

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
KR 1020240018510-A2024-02-13

THERAPEUTICS AND METHODS FOR TREATING OR AMELIORATING METABOLIC DISORDERS

SWIFTNOVO THERAPEUTICS INC

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
JP 2024522376-A2024-06-18

Therapeutics and Methods for Treating or Ameliorating Metabolic Disorders

Dragonstone Holding (Hong Kong) Limited

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
EP 4440615-A12024-10-09

TRANSFERRIN BINDING ANTIBODIES AND USE THEREOF

LINNO PHARMACEUTICALS INC

Query Match 88.2%Identity 92.9%Family of 2
Best alignment and family
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- EP 4440615-A12024-10-09
- US 12144866-B22024-11-19
US 12122817-B22024-10-22

Long-lasting GLP1 analogue drug for type-2 diabetes

SERPENTIDE INC.

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
KR 1020240153528-A2024-10-23

FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

MEDI&GENE

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
KR 1020250044400-A2025-03-31

FUNCTION-ENHANCED ENGINEERED EBNA1 FOR PROTEIN EXPRESSION IN MAMMALIAN CELLS

WuXi Biologics Ireland Limited

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
KR 1020250092302-A2025-06-24

EXPRESSION VECTOR FOR LONG R3 IGF-1 AND USE THEREOF

Rophibio, Inc

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 37 to 67. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit   37 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 67
```
28 of 31 identical, no gaps.
JP 2025525046-A2025-08-01

FUNCTION-ENHANCED ENGINEERED EBNA1 FOR PROTEIN EXPRESSION IN MAMMALIAN CELLS

WUXI BIOLOGICS (SHANGHAI) CO., LTD

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
EP 4595977-A12025-08-06

ULTRA-LONG-ACTING PLATFORM COMPRISING FC-ADVANCED FATTY ACID CHAIN

WATERSTONE PHARMACEUTICALS WUHAN CO LTD

Query Match 88.2%Identity 90.3%Family of 2
Best alignment and family
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- EP 4595977-A12025-08-06
- JP 2025535871-A2025-10-30
KR 1020250128374-A2025-08-27

METHODS OF DULAGLUTIDE PURIFICATION USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY

Eli Lilly and Company

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
EP 4642789-A12025-11-05

METHODS OF DULAGLUTIDE PURIFICATION USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY

LILLY CO ELI

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
KR 1020250169641-A2025-12-03

CODON OPTIMIZATION AND METHODS OF USE THEREOF

GENERAL MEDICINES LLC

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 32 to 62. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit   32 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 62
```
28 of 31 identical, no gaps.
EP 4676522-A12026-01-14

CODON OPTIMIZATION AND METHODS OF USE THEREOF

GENERAL MEDICINES LLC

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 32 to 62. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit   32 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 62
```
28 of 31 identical, no gaps.
EP 4696707-A12026-02-18

SINGLE FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

MEDI&GENE INC

Query Match 88.2%Identity 90.3%Family of 2
Best alignment and family
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- EP 4696707-A12026-02-18
- JP 2026513837-A2026-05-01
JP 2026508559-A2026-03-11

CODON OPTIMIZATION AND METHODS OF USE THEREOF

GENERAL MEDICINES LLC

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 32 to 62. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit   32 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 62
```
28 of 31 identical, no gaps.
EP 4732829-A12026-04-29

GLP-1-FC-FGF21 DOUBLE-TARGET FUSION PROTEIN COMPOSITION, AND INJECTION AND USE THEREOF

SUNSHINE LAKE PHARMA CO LTD

Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||||||||||||| |
Hit    1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 31
```
28 of 31 identical, no gaps.
US 5512549-A1996-04-30

Glucagon-like insulinotropic peptide analogs, compositions, and methods of use

Query Match 87.6%Identity 96.6%
Best alignment
Query 2 to 30, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  2 AEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
         |||||||||||||||||| ||||||||||
Hit    1 AEGTFTSDVSSYLEGQAAXEFIAWLVKGR 29
```
28 of 29 identical, no gaps.
EP 1227151-A12002-07-31

Glucagon-like insulinotropic peptide analogs, compositions, and methods of use

ELI LILLY AND COMPANY (US)

Query Match 87.6%Identity 96.6%
Best alignment
Query 2 to 30, hit 2 to 30. Positions start at 1 and include both ends.
```
Query  2 AEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
         |||||||||||||||||| ||||||||||
Hit    2 AEGTFTSDVSSYLEGQAAXEFIAWLVKGR 30
```
28 of 29 identical, no gaps.
US 6573237-A2003-06-03

Protein formulations

Eli Lilly and Company

Query Match 87.6%Identity 100.0%
Best alignment
Query 2 to 30, hit 2 to 30. Positions start at 1 and include both ends.
```
Query  2 AEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30
         |||||||||||||||||| ||||||||||
Hit    2 AEGTFTSDVSSYLEGQAAXEFIAWLVKGR 30
```
28 of 29 identical, no gaps.
WO 2008145721-A22008-12-04

N-terminal modification of polypeptides for protection against degradation by aminopeptidases

Novo Nordisk A/S (DK)

Query Match 87.6%Identity 93.3%
Best alignment
Query 2 to 31, hit 2 to 31. Positions start at 1 and include both ends.
```
Query  2 AEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         |||||||||||||||||| ||||||| |||
Hit    2 AEGTFTSDVSSYLEGQAAXEFIAWLVXGRG 31
```
28 of 30 identical, no gaps.
JP 2022551716-A2022-12-13

GLP-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof

SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD, HANGZHOU SINOPEP-ALLSINO PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO LTD

Query Match 87.6%Identity 87.1%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         | ||||||||||||| ||| ||||||| |||
Hit    1 HXEGTFTSDVSSYLEXQAAXEFIAWLVRGRG 31
```
27 of 31 identical, no gaps.
EP 2460825-A12012-06-06

DERIVATIVE OF GLP-1 ANALOGUE OR ITS PHARMACEUTICAL SALTS AND THEIR USE

JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD

Query Match 87.0%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 30. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         ||||||||||||||||||| ||| |||||||
Hit    1 HAEGTFTSDVSSYLEGQAA-EFIVWLVKGRG 30
```
29 of 31 identical, 1 gap.
JP 2013500278-A2013-01-07

GLP-1 ANALOGUES AND THEIR PHARMACEUTICAL SALTS AND USES

JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD,Yali WANG,Aifeng LU,Changan SUN, Hengli YUAN

Query Match 87.0%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 30. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         ||||||||||||||||||| ||| |||||||
Hit    1 HAEGTFTSDVSSYLEGQAA-EFIVWLVKGRG 30
```
29 of 31 identical, 1 gap.
KR 1020150064093-A2015-06-10

EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS

SANOFI

Query Match 87.0%Identity 96.7%Family of 4
Best alignment and family
Query 1 to 31, hit 1 to 30. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31
         ||||||||||||||||||||| ||||| |||
Hit    1 HAEGTFTSDVSSYLEGQAAKE-IAWLVRGRG 30
```
29 of 31 identical, 1 gap.
Family of 4
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020150064093-A2015-06-10
- JP 2015532297-A2015-11-09
- US 9365632-B22016-06-14
- US 10758592-B22020-09-01
KR 1020170104409-A2017-09-15

Polyethylene glycol derivatives and use thereof

HANMI PHARM. CO., LTD

Query Match 87.0%Identity 89.7%Family of 2
Best alignment and family
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020170104409-A2017-09-15
- JP 2019515972-A2019-06-13
EP 3398961-A12018-11-07

TRIPLE ACTIVATOR ACTIVATING GLUCAGON, GLP-1 AND GIP RECEPTOR

HANMI PHARM IND CO LTD

Query Match 87.0%Identity 89.7%
Best alignment
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
EP 3398962-A12018-11-07

PERSISTENT CONJUGATE OF TRIPLE ACTIVATOR ACTIVATING GLUCAGON, GLP-1 AND GIP RECEPTOR

HANMI PHARM IND CO LTD

Query Match 87.0%Identity 89.7%
Best alignment
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
EP 3428147-A12019-01-16

POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF

HANMI PHARM IND CO LTD

Query Match 87.0%Identity 89.7%
Best alignment
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
JP 2019504055-A2019-02-14

LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST

HANMI PHARM CO LTD

Query Match 87.0%Identity 89.7%Family of 2
Best alignment and family
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- JP 2019504055-A2019-02-14
- US 10400020-B22019-09-03
JP 2019504057-A2019-02-14

TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST

HANMI PHARM CO LTD

Query Match 87.0%Identity 89.7%Family of 3
Best alignment and family
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
Family of 3
Grouped by the same title and applicant. No priority claim is on record.
- JP 2019504057-A2019-02-14
- US 10370426-B22019-08-06
- US 11332508-B22022-05-17
KR 1020190060749-A2019-06-03

Long acting conjugate of Trigonal glucagon/GLP-1/GIP receptor agonist

HANMI PHARM. CO., LTD

Query Match 87.0%Identity 89.7%Family of 3
Best alignment and family
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
Family of 3
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020190060749-A2019-06-03
- KR 1020190104958-A2019-09-11
- KR 1020200095436-A2020-08-10
KR 1020190062344-A2019-06-05

Trigonal glucagon/GLP-1/GIP receptor agonist

HANMI PHARM. CO., LTD

Query Match 87.0%Identity 89.7%Family of 3
Best alignment and family
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
Family of 3
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020190062344-A2019-06-05
- KR 1020190105542-A2019-09-17
- KR 1020200096184-A2020-08-11
WO 2020044204-A12020-03-05

METHODS OF PREPARING STABLE LIQUID THERAPEUTIC PROTEIN COMPOSITIONS

GLAXOSMITHKLINE IP DEV LTD

Query Match 87.0%Identity 96.4%
Best alignment
Query 1 to 28, hit 1 to 28. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVK 28
         | ||||||||||||||||||||||||||
Hit    1 HGEGTFTSDVSSYLEGQAAKEFIAWLVK 28
```
27 of 28 identical, no gaps.
KR 1020200078413-A2020-07-01

A pharmaceutical composition comprising insulin and trigonal glucagon/GLP-1/GIP receptor agonist

HANMI PHARM. CO., LTD

Query Match 87.0%Identity 89.7%Family of 2
Best alignment and family
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020200078413-A2020-07-01
- JP 2022515229-A2022-02-17
KR 1020210002055-A2021-01-06

Therapeutic use of Trigonal glucagon/GLP-1/GIP receptor agonist or a conjugate thereof for liver disease

HANMI PHARM. CO., LTD

Query Match 87.0%Identity 89.7%Family of 4
Best alignment and family
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
Family of 4
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020210002055-A2021-01-06
- KR 1020210002067-A2021-01-06
- JP 2022530714-A2022-06-30
- KR 1020220146369-A2022-11-01
KR 1020210091032-A2021-07-21

Long acting conjugate of Trigonal glucagon/GLP-1/GIP receptor agonist for use in the treatment of pulmonary disease

HANMI PHARM. CO., LTD

Query Match 87.0%Identity 89.7%Family of 2
Best alignment and family
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020210091032-A2021-07-21
- JP 2023510864-A2023-03-15
KR 1020210129614-A2021-10-28

Composition for prevention or treatment of hyperlipidemia comprising Trigonal glucagon/GLP-1/GIP receptor agonist or a conjugate thereof and method using the same

HANMI PHARM. CO., LTD

Query Match 87.0%Identity 89.7%Family of 2
Best alignment and family
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.
Family of 2
Grouped by the same title and applicant. No priority claim is on record.
- KR 1020210129614-A2021-10-28
- JP 2023521491-A2023-05-24
KR 1020220010462-A2022-01-25

Therapeutic use of a combination comprising triple agonistic long-acting conjugate or triple agonist

HANMI PHARM. CO., LTD

Query Match 87.0%Identity 89.7%
Best alignment
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
```
Query  1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29
         |  ||||||||||| ||||||||||||||
Hit    1 HXQGTFTSDVSSYLDGQAAKEFIAWLVKG 29
```
26 of 29 identical, no gaps.

GLP-1, a diabetes hormone

The search

Patents

Family of 8

Family of 3

Family of 2

Family of 2

Family of 2

Family of 2

Family of 2

Family of 2

Family of 4

Family of 2

Family of 2

Family of 3

Family of 3

Family of 3

Family of 2

Family of 4

Family of 2

Family of 2